| editorial | Q871232 |
| scholarly article | Q13442814 |
| P2093 | author name string | Mahmoud Aboelneen Khattab | |
| Mohammed Eslam | |||
| P2860 | cites work | Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 |
| Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3 | Q27477554 | ||
| Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C | Q27477981 | ||
| Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C | Q27478298 | ||
| Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 | Q27478313 | ||
| STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? | Q27478329 | ||
| Targeting host factors: A novel rationale for the management of hepatitis C virus | Q27488999 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| The lipid droplet is an important organelle for hepatitis C virus production | Q28131709 | ||
| Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice | Q28144106 | ||
| Immunosenescence and infectious diseases | Q28189712 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus | Q28279955 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening | Q45733968 | ||
| Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. | Q45923009 | ||
| Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. | Q47675220 | ||
| Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. | Q50571973 | ||
| Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. | Q50582517 | ||
| Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. | Q50585022 | ||
| Natural history of hepatitis C | Q73717361 | ||
| Nucleotide sequence and mutation rate of the H strain of hepatitis C virus | Q29619801 | ||
| Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. | Q31040495 | ||
| Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. | Q33350754 | ||
| Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data | Q33404846 | ||
| Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin | Q33905877 | ||
| Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. | Q34065725 | ||
| Associations between serum lipids and hepatitis C antiviral treatment efficacy | Q34124888 | ||
| Fibrosis and disease progression in hepatitis C. | Q34984040 | ||
| Host factors and failure of interferon-alpha treatment in hepatitis C virus | Q35730979 | ||
| Insulin resistance and hepatitis C: an evolving story | Q37830948 | ||
| Management of hepatitis C virus genotype 4: recommendations of an international expert panel. | Q37840716 | ||
| Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy | Q39133337 | ||
| Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. | Q39845360 | ||
| Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. | Q39981071 | ||
| Nomenclature and numbering of the hepatitis C virus | Q40027957 | ||
| Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. | Q40078224 | ||
| The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms | Q40140184 | ||
| IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. | Q40674809 | ||
| Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens | Q42446341 | ||
| Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. | Q42456523 | ||
| Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin | Q42929942 | ||
| Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection | Q42978401 | ||
| Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. | Q42981658 | ||
| Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads | Q42982601 | ||
| Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection | Q42984502 | ||
| Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. | Q42984907 | ||
| Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. | Q42985188 | ||
| Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients | Q42988204 | ||
| Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin | Q42990261 | ||
| Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. | Q42990374 | ||
| Genomics: Hepatitis C virus gets personal | Q42991039 | ||
| Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance | Q42992778 | ||
| Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients | Q42995429 | ||
| Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy | Q42997897 | ||
| An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response | Q42998430 | ||
| Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. | Q43032172 | ||
| IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. | Q43034706 | ||
| Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection | Q43035013 | ||
| Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. | Q43041821 | ||
| Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus | Q43041991 | ||
| Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. | Q43046800 | ||
| Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. | Q43047842 | ||
| Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis | Q43047910 | ||
| A proposed system for the nomenclature of hepatitis C viral genotypes | Q43049109 | ||
| Direct economic burden of chronic hepatitis C virus in a United States managed care population | Q44154823 | ||
| Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. | Q44643929 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis C virus | Q708693 |
| P304 | page(s) | 235-241 | |
| P577 | publication date | 2012-04-30 | |
| P1433 | published in | Hepatitis Monthly | Q15734417 |
| P1476 | title | The impact of host factors on management of hepatitis C virus | |
| P478 | volume | 12 |
Search more.